A 3-gene PI stratifies survival in adult patients with AML (discovery series). (A) Distribution of AML patients from 5 independent cohorts by PI group. (B) Distribution of AML patients with low, intermediate, and high PI by World Health Organization category.2 (C) Distribution of AML patients with low, intermediate, and high PI by ELN cytogenetic risk categories. Comparisons were performed using the χ2 test. (D) Distribution of AML patients with low, intermediate, and high PI by age groups. Comparisons were performed using the χ2 test. (E) Distribution of AML patients with low, intermediate, and high PI by treatment received. Comparisons were performed using the χ2 test. (F) Kaplan-Meier estimates of EFS and OS in AML patients stratified based on ELN cytogenetic risk. Survival curves were compared using a log-rank (Mantel-Cox) test. (G) Kaplan-Meier estimates of EFS and OS in AML patients stratified based on our 3-gene PI. NS, not significant.